Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap

References

• PappZ, AgostoniP, AlvarezJ, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use. Card Fail Rev. 2020;6:e19. doi:10.15420/cfr.2020.0332714567
   PubMedGoogle Scholar
• GordonAC, PerkinsGD, SingerM, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med. 2016;375(17):1638–1648. doi:10.1056/NEJMoa160940927705084
   PubMed Web of Science ®Google Scholar
• AntcliffeDB, SanthakumaranS, OrmeRML, et al. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. Intensive Care Med. 2019;45:1392–1400. doi:10.1007/s00134-019-05731-w31428804
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EU/3/18/1980. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3181980. Accessed 329, 2021.
   Google Scholar
• Al-ChalabiA, HeunksLMA, PappZ, PolleselloP. Potential of the cardiovascular drug levosimendan in the management of amyotrophic lateral sclerosis: an overview of a working hypothesis. J Cardiovasc Pharmacol. 2019;74:389–399. doi:10.1097/FJC.000000000000072831730560
   PubMed Web of Science ®Google Scholar
• AntilaS, SundbergS, LehtonenLA. Clinical pharmacology of levosimendan. Clin Pharmacokinet. 2007;46(7):535–552. doi:10.2165/00003088-200746070-0000117596101
   PubMed Web of Science ®Google Scholar
• ClelandJGF, NikitinN, JamesM. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. Expert Rev Cardiovasc Ther. 2004;2:9–19. doi:10.1586/14779072.2.1.915038409
   PubMedGoogle Scholar
• PuttonenJ, KanteleS, KivikkoM, et al. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet. 2007;46(3):235–246. doi:10.2165/00003088-200746030-0000417328582
   PubMed Web of Science ®Google Scholar
• FollathF, ClelandJG, JustH, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360(9328):196–202. doi:10.1016/S0140-6736(02)09455-212133653
   PubMed Web of Science ®Google Scholar
• MebazaaA, NieminenMS, PackerM, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297(17):1883–1891. doi:10.1001/jama.297.17.188317473298
   PubMed Web of Science ®Google Scholar
• FiggittDP, GilliesPS, GoaKL. Levosimendan. Drugs. 2001;61:613–627; discussion 628–9. doi:10.2165/00003495-200161050-00006
   Web of Science ®Google Scholar
• AntoniadesC, TousoulisD, KoumallosN, MarinouK, StefanadisC. Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol Ther. 2007;114(2):184–197. doi:10.1016/j.pharmthera.2007.01.00817363065
   PubMed Web of Science ®Google Scholar
• GongB, LiZ, Yat WongPC. Levosimendan treatment for heart failure: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2015;29(6):1415–1425. doi:10.1053/j.jvca.2015.03.02326275522
   PubMed Web of Science ®Google Scholar
• PonikowskiP, VoorsAA, AnkerSD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.27206819
   PubMed Web of Science ®Google Scholar
• YilmazMB, GrossiniE, Silva CardosoJC, et al. Renal effects of levosimendan: a consensus report. Cardiovasc Drugs Ther. 2013;27(6):581–590. doi:10.1007/s10557-013-6485-623929366
   PubMed Web of Science ®Google Scholar
• FedeleF, BrunoN, BrasolinB, CairaC, D’AmbrosiA, ManconeM. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014;16(3):281–288. doi:10.1002/ejhf.924464960
   PubMed Web of Science ®Google Scholar
• LannemyrL, RickstenS-E, RundqvistB, et al. Differential effects of levosimendan and dobutamine on glomerular filtration rate in patients with heart failure and renal impairment: a randomized double-blind controlled trial. J Am Heart Assoc. 2018;7:e008455. doi:10.1161/JAHA.117.00845530369310
   PubMed Web of Science ®Google Scholar
• NieminenMS, AkkilaJ, HasenfussG, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36(6):1903–1912. doi:10.1016/S0735-1097(00)00961-X11092663
   PubMed Web of Science ®Google Scholar
• SlawskyMT, ColucciWS, GottliebSS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000;102(18):2222–2227. doi:10.1161/01.CIR.102.18.222211056096
   PubMed Web of Science ®Google Scholar
• MoiseyevVS, PõderP, AndrejevsN, et al. Safety and efficacy of a novel calcium sensitiser, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422–1432. doi:10.1053/euhj.2001.315812208222
   PubMed Web of Science ®Google Scholar
• PackerM, ColucciW, FisherL, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1:103–111. PMID: 12133653. doi:10.1016/s0140-6736(02)09455-224621834
   PubMed Web of Science ®Google Scholar
• LandoniG, Biondi-ZoccaiG, GrecoM, et al. Effects of levosimendan on mortality and hospitalization. A metaanalysis of randomized controlled studies. Crit Care Med. 2012;40:634–646. doi:10.1097/CCM.0b013e318232962a21963578
   PubMed Web of Science ®Google Scholar
• MebazaaA, NieminenMS, FilippatosGS, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009;11:304–311. doi:10.1093/eurjhf/hfn04519158152
   PubMed Web of Science ®Google Scholar
• BerghCH, AnderssonB, DahlstromU, et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail. 2010;12:404–410. doi:10.1093/eurjhf/hfq03220335355
   PubMed Web of Science ®Google Scholar
• NieminenMS, BuerkeM, Cohen-SolálA, et al. The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion. Int J Cardiol. 2016;218:150–157. doi:10.1016/j.ijcard.2016.05.00927232927
   PubMed Web of Science ®Google Scholar
• SonntagS, SundbergS, LehtonenLA, KleberFX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43(12):2177–2182. doi:10.1016/j.jacc.2004.02.05215193677
   PubMed Web of Science ®Google Scholar
• De LucaL, ProiettiP, CelottoA, et al. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J. 2005;150(3):563–568. doi:10.1016/j.ahj.2004.10.01316169341
   PubMed Web of Science ®Google Scholar
• JiaZ, GuoM, ZhangYQ, LiangHQ, ZhangLY, SongY. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction. Cardiology. 2014;128:195–201. doi:10.1159/00035786424751462
   PubMed Web of Science ®Google Scholar
• HusebyeT, EritslandJ, MüllerC, et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail. 2013;15(5):565–572. doi:10.1093/eurjhf/hfs21523288914
   PubMed Web of Science ®Google Scholar
• HansenMS, AndersenA, Nielsen-KudskJE. Levosimendan in pulmonary hypertension and right heart failure. Pulm Circ. 2018;8(3):2045894018790905. doi:10.1177/204589401879090529979110
   PubMed Web of Science ®Google Scholar
• ParissisJT, ParaskevaidisI, BistolaV, et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol. 2006;98(11):1489–1492. doi:10.1016/j.amjcard.2006.06.05217126656
   PubMed Web of Science ®Google Scholar
• RussMA, ProndzinskyR, CarterJM, et al. Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendan. Crit Care Med. 2009;37(12):3017–3023. doi:10.1097/CCM.0b013e3181b0314a19661807
   PubMed Web of Science ®Google Scholar
• PoelzlG, ZwickRH, GranderW, et al. Safety and effectiveness of levosimendan in patients with predominant right heart failure. Herz. 2008;33:368–373. doi:10.1007/s00059-008-3051-218773157
   PubMed Web of Science ®Google Scholar
• QiuJ, JiaL, HaoY, et al. Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis. Life Sci. 2017;184:30–36. doi:10.1016/j.lfs.2017.07.00128689804
   PubMed Web of Science ®Google Scholar
• MebazaaA, ParissisJ, PorcherR, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011;37:290–301. doi:10.1007/s00134-010-2073-421086112
   PubMed Web of Science ®Google Scholar
• MebazaaA, MotiejunaiteJ, GayatE, et al; Long-Term Registry Investigators. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European society of cardiology heart failure long-term registry. Eur J Heart Fail. 2018;20:332–341. doi:10.1002/ejhf.99128990358
   PubMed Web of Science ®Google Scholar
• FuhrmannJT, SchmeisserA, SchulzeMR, et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2008;36(8):2257–2266. doi:10.1097/CCM.0b013e318180984618664782
   PubMed Web of Science ®Google Scholar
• García-GonzálezMJ, Domínguez-RodríguezA, Ferrer-HitaJJ, et al. Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail. 2006;8(7):723–728. doi:10.1016/j.ejheart.2006.01.00716492404
   PubMed Web of Science ®Google Scholar
• Dominguez-RodriguezA, Samimi-FardS, Garcia-GonzalezMJ, et al. Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty. Int J Cardiol. 2008;128(2):214–217. doi:10.1016/j.ijcard.2007.05.01817643535
   PubMed Web of Science ®Google Scholar
• Samimi-FardS, García-GonzálezMJ, Domínguez-RodríguezA, et al. Effects of levosimendan versus dobutamine on longterm survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol. 2008;127:284–287. doi:10.1016/j.ijcard.2007.04.14317643519
   PubMed Web of Science ®Google Scholar
• ChristophA, ProndzinskyR, RussM, et al. Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction. Acute Card Care. 2008;10:49–57. doi:10.1080/1748294070135856417924229
   PubMedGoogle Scholar
• OmerovicE, RåmunddalT, AlbertssonP, et al. Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction. Vasc Health Risk Manag. 2010;6:657–663. doi:10.2147/VHRM.S885620859537
   PubMedGoogle Scholar
• RussMA, ProndzinskyR, ChristophA, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med. 2007;35:2732–2739.17893627
   PubMed Web of Science ®Google Scholar
• SchumannJ, HenrichEC, StroblH, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018;1:CD009669.29376560
   PubMed Web of Science ®Google Scholar
• FangM, CaoH, WangZ. Levosimendan in patients with cardiogenic shock complicating myocardial infarction: a meta-analysis. Med Int. 2018;42:409–415.
   Google Scholar
• ChioncelO, ParissisJ, MebazaaA, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European society of cardiology. Eur J Heart Fail. 2020;22:1315–1341. doi:10.1002/ejhf.192232469155
   PubMed Web of Science ®Google Scholar
• LyonAR, BossoneE, SchneiderB, et al. Current state of knowledge on takotsubo syndrome: a position statement from the taskforce on takotsubo syndrome of the Heart Failure Association of the European society of cardiology. Eur J Heart Fail. 2016;18:8–27. doi:10.1002/ejhf.424
   PubMed Web of Science ®Google Scholar
• HeringD, JaguszewskiM. Levosimendan: new hope therapy for takotsubo syndrome. Cardiol J. 2016;23(6):616–617. doi:10.5603/CJ.2016.010127976790
   PubMed Web of Science ®Google Scholar
• De SantisV, VitaleD, TritapepeL, et al. Use of levosimendan for cardiogenic shock in a patient with the apical ballooning syndrome. Ann Intern Med. 2008;149(5):365–367. doi:10.7326/0003-4819-149-5-200809020-0002818765717
   PubMed Web of Science ®Google Scholar
• AbramsD, CombesA, BrodieD. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol. 2014;63(25):2769–2778. doi:10.1016/j.jacc.2014.03.04624814488
   PubMed Web of Science ®Google Scholar
• AffrontiA, Di BellaI, CarinoD, RagniT. Levosimendan may improve weaning outcomes in venoarterial ECMO patients. ASAIO J. 2013;59:554–557. doi:10.1097/MAT.0b013e3182a4b32e24172260
   PubMed Web of Science ®Google Scholar
• SangalliF, AvalliL, LarattaM, et al. Effects of levosimendan on endothelial function and hemodynamics during weaning from veno-arterial extracorporeal life support. J Cardiothorac Vasc Anesth. 2016;30(6):1449–1453. doi:10.1053/j.jvca.2016.03.13927495966
   PubMed Web of Science ®Google Scholar
• JackyA, RudigerA, KrügerB, et al. Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery – a retrospective before and after study. J Cardiothorac Vasc Anesth. 2018;32:2112–2119. doi:10.1053/j.jvca.2018.04.01929748076
   PubMed Web of Science ®Google Scholar
• DistelmaierK, RothC, SchrutkaL, et al. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth. 2016;117:52–58.27317704
   PubMed Web of Science ®Google Scholar
• VallyS, FerdynusC, PersichiniR, et al. Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit. Ann Intensive Care. 2019;9(1):24.30707314
   PubMed Web of Science ®Google Scholar
• GuilhermeE, Jacquet-LagrèzeM, PozziM, AchanaF, ArmoiryX, FellahiJL. Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis. Crit Care. 2020;24:442. doi:10.1186/s13054-020-03122-y32677985
   PubMed Web of Science ®Google Scholar
• Alonso-Fernandez-GattaM, Merchan-GomezS, Gonzalez-CebrianM, et al. Levosimendan in veno-arterial extracorporeal membrane oxygenator supported patients: impact on the success of weaning and survival. Artif Organs. 2021;45:717–725. doi:10.1111/aor.13899
   Web of Science ®Google Scholar
• PirracchioR, ParenicaJ, Resche RigonM, et al; GREAT network. The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis. PLoS One. 2013;8(8):e71659. Erratum in: PLoS One. 2013; 8(12). doi:10.1371/journal.pone.007165923977106
   PubMed Web of Science ®Google Scholar
• TarvasmäkiT, LassusJ, VarpulaM, et al; CardShock study investigators. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Crit Care. 2016;20(1):208. doi:10.1186/s13054-016-1387-127374027
   PubMed Web of Science ®Google Scholar
• PölzlG, AltenbergerJ, BaholliL, et al. Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. Int J Cardiol. 2017;243:389–395. doi:10.1016/j.ijcard.2017.05.08128571618
   PubMed Web of Science ®Google Scholar
• AltenbergerJ, ParissisJT, Costard-JaeckleA, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail. 2014;16:898–906. doi:10.1002/ejhf.11824920349
   PubMed Web of Science ®Google Scholar
• Comín-ColetJ, ManitoN, Segovia-CuberoJ, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018;20(7):1128–1136. doi:10.1002/ejhf.114529405611
   PubMed Web of Science ®Google Scholar
• LAICA Study Investigators. Efficacy and security of intermittent repeated levosimendan administration in patients with advanced heart failure: a randomized, double-blind, placebo controlled multicenter trial: LAICA study. Presented at the European Society of Cardiology–Heart Failure Association Congress; May 21; 2016; Florence, Italy.
   Google Scholar
• ThorvaldsenT, BensonL, HagermanI, DahlströmU, EdnerM, LundLH. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden. Int J Cardiol. 2014;175:55–61.24820737
   PubMed Web of Science ®Google Scholar
• OlivaF, PernaE, MariniM, et al; RELEVANT-HF study group. Scheduled intermittent inotropes for ambulatory advanced heart failure. The RELEVANT-HF multicentre collaboration. Int J Cardiol. 2018;272:255–259.30131229
   PubMed Web of Science ®Google Scholar
• PölzlG, Allipour BirganiS, Comín-ColetJ, et al. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. ESC Heart Fail. 2019;6:174–181. doi:10.1002/ehf2.1236630378288
   PubMed Web of Science ®Google Scholar
• MebazaaA, PitsisAA, RudigerA, et al. Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care. 2010;14(2):201. doi:10.1186/cc815320497611
   PubMed Web of Science ®Google Scholar
• HarrisonRW, HasselbladV, MehtaRH, et al. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2013;27(6):1224–1232. doi:10.1053/j.jvca.2013.03.02724050857
   PubMed Web of Science ®Google Scholar
• SanfilippoF, KnightJB, ScollettaS, et al. Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis. Crit Care. 2017;21(1):252. doi:10.1186/s13054-017-1849-029047417
   PubMed Web of Science ®Google Scholar
• CholleyB, CarubaT, GrosjeanS, et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA. 2017;318(6):548–556. doi:10.1001/jama.2017.997328787507
   PubMed Web of Science ®Google Scholar
• MehtaRH, LeimbergerJD, van DiepenS, et al; LEVO-CTS Investigators. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. 2017;376(21):2032–2042. doi:10.1056/NEJMoa161621828316276
   PubMed Web of Science ®Google Scholar
• LandoniG, LomivorotovVV, AlvaroG, et al. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med. 2017;376:2021–2031.28320259
   PubMed Web of Science ®Google Scholar
• PutzuA, ClivioS, BellettiA, CassinaT. Perioperative levosimendan in cardiac surgery: a systematic review with meta-analysis and trial sequential analysis. Int J Cardiol. 2018;251:22–31. doi:10.1016/j.ijcard.2017.10.07729126653
   PubMed Web of Science ®Google Scholar
• GuarracinoF, HeringlakeM, CholleyB, et al. Use of levosimendan in cardiac surgery: an update after the LEVOCTS, CHEETAH, and LICORN trials in the light of clinical practice. J Cardiovasc Pharmacol. 2018;71:1–9. doi:10.1097/FJC.000000000000055129076887
   PubMed Web of Science ®Google Scholar
• HabicherM, ZajonzT, HeringlakeM, et al. S3-Leitlinie zur intensivmedizinischen Versorgung herzchirurgischer Patienten: Hämodynamisches Monitoring und Herz-Kreislauf – ein Update [S3 guidelines on intensive medical care of cardiac surgery patients: hemodynamic monitoring and cardiovascular system-an update]. Anaesthesist. 2018;67:375–379. German.29644444
   PubMed Web of Science ®Google Scholar
• WangW, ZhouX, LiaoX, LiuB, YuH. The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft: a systematic review and meta-analysis. J Anesth. 2019;33:543–550. doi:10.1007/s00540-019-02643-331025104
   PubMed Web of Science ®Google Scholar
• van DiepenS, MehtaRH, LeimbergerJD, et al. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. J Thorac Cardiovasc Surg. 2020;159(6):2302–2309.e6. doi:10.1016/j.jtcvs.2019.06.02031358329
   PubMed Web of Science ®Google Scholar
• TheissHD, GrabmaierU, KreisslN, et al. Preconditioning with levosimendan before implantation of left ventricular assist devices. Artif Organs. 2014;38(3):231–234. doi:10.1111/aor.1215024147881
   PubMed Web of Science ®Google Scholar
• KocabeyogluSS, KervanU, SertDE, et al. Optimization with levosimendan improves outcomes after left ventricular assist device implantation. Eur J Cardiothorac Surg. 2020;57(1):176–182. doi:10.1093/ejcts/ezz15931155645
   PubMed Web of Science ®Google Scholar
• TreskatschS, BalzerF, GeyerT, et al. Early levosimendan administration is associated with decreased mortality after cardiac surgery. J Crit Care. 2015;30(4):859.e1–6. doi:10.1016/j.jcrc.2015.03.008
   Web of Science ®Google Scholar
• ÁvalosR, MartinezSanzR, JiménezJ, et al. Levosimendan preconditioning in patients undergoing elective cardiac surgery with poor ejection fraction. preliminary results. J Cardiothorac Surg. 2015;10:A310. doi:10.1186/1749-8090-10-S1-A310
   Google Scholar
• HeringlakeM, AlvarezJ, BettexD, et al. An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. Expert Rev Cardiovasc Ther. 2021;19(4):325–335. doi:10.1080/14779072.2021.190552033739204
   PubMed Web of Science ®Google Scholar